Previous 10 | Next 10 |
2024-06-28 07:45:00 ET The stock market has its ups and downs -- and if you stay invested for decades, you will likely experience your fair share of both bull and bear markets. At the same time, by investing in a diverse assortment of stocks across various industries, risk profiles, and bus...
2024-06-28 05:50:00 ET Believe it or not, we're nearly halfway through this decade. The healthcare sector could be in store for monumental changes over the next few years. These changes should present great opportunities for investors to make money. But where should they put their money...
2024-06-27 15:21:32 ET Summary bluebird bio, Inc. stock plummeted by 73% amid financial struggles and operational hurdles post FDA approval of their gene therapy Lyfgenia. The company faces intense competition from CRISPR Therapeutics' Casgevy, which benefits from stronger resourc...
2024-06-27 14:02:20 ET More on S&P 500 Index: The Greenback Consolidates While Sustaining A Break Against The Yen Fed Update: The Fed Has A Mortgage-Backed Securities Problem Market Breadth Will Improve As The Soft Landing Comes Into View Nasdaq, S&P,...
2024-06-26 12:31:01 ET Volume away from semiconductor ETFs’ ( SMH ), ( SEMI ), ( NASDAQ: SOXX ) overbought conditions could mean some long-term bullishness with other parts of the market seeing gains, according to an Argus Research Market Movers note.... Read th...
2024-06-25 09:00:00 ET Summary Catalent stock rose 3% after Elevidys label expansion approval by the FDA. Sarepta's stock reached an all-time high after Elevidys label expansion approval. Several companies including PFE, CAPR, RGNX, SLDB, VRTX, have DMD gene-therapy product candid...
2024-06-25 04:12:00 ET Vertex Pharmaceuticals (NASDAQ: VRTX) recently excited the medical community with clinical trial results from an experimental diabetes treatment it's developing. In a nutshell, it looks like a single infusion of VX-880 allowed a dozen diabetes patients to begi...
2024-06-24 08:15:04 ET Wells Fargo analyst issues OVERWEIGHT recommendation for VRTX on June 24, 2024 07:08AM ET. The previous analyst recommendation was Overweight. VRTX was trading at $468.71 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-06-21 16:53:53 ET More on Vertex Pharmaceuticals Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales Vertex Pharmaceuticals Incorporated (VRTX) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Vertex Pharmaceuticals Incorpor...
– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 – – All patients achieved ADA-recommended target HbA1c levels <7.0% and >70% time-in-range (70-180...
News, Short Squeeze, Breakout and More Instantly...
Vertex Pharmaceuticals Incorporated Company Name:
VRTX Stock Symbol:
NASDAQ Market:
Vertex Pharmaceuticals Incorporated Website:
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...